MAM
Castrol India taps Deepesh Baxi as CFO and wholetime director
NEW DELHI: Castrol India has tapped Deepesh Baxi to succeed Rashmi Joshi as chief financial officer (CFO) and wholetime director, as the latter steps down from her current position on 31 December 2020.
Baxi, who is currently financial controller for Castrol’s businesses globally, will take up the role and join the Board on 1 January 2021. Joshi will move to another leadership position in BP after having served Castrol India for seven years as CFO and wholetime director. Joshi and Baxi will work together between now and the end of December to ensure a seamless transition.
Castrol India chairman R Gopalakrishnan said, “Rashmi has played a key leadership role offering financial stewardship and strategic insights to the business as it undertook several successful transitions during her tenure as CFO. On behalf of the board, I would like to thank Rashmi for all she has done for Castrol India and extend a warm welcome to Deepesh.”
Castrol India MD Sandeep Sangwan added, “Having worked with Rashmi for close to a year now, I value her financial expertise, strategic guidance and commitment to strengthen the financial health of the business. I wish her success in her new role and look forward to working with Deepesh who will bring his rich, cross-cultural global experience to lead the strategic financial agenda for Castrol India.”
Baxi is a chartered accountant with over two decades of industry and consulting experience, having spent the last 18 years in various roles within BP. He is also an alumnus of Indian Institute of Management (IIM), Ahmedabad and a certified internal auditor from Institute of Internal Auditors, USA. He has worked in international markets including UK and Asia Pacific in several leadership roles spanning across finance, strategy, M&A, planning, audit, risk and compliance, as well as business transformation.
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
